Best of March: Top 5 Insights in Clinical Research

#1 - No Surprise: Patient Recruitment Still Sucks

Patient recruitment expert Ross Jackson talks about why this part of the clinical trials ecosystem is still a problem and offers up some solutions, specifically around digital/social media outreach.

#2 - 4 Insights For 2024: An Interview With Ken Getz And Jim Murphy

In this on-demand webinar, industry experts Ken Getz and Jim Murphy provide insights into the anticipated trends within the clinical trial landscape for 2024. Gain a comprehensive understanding of the future direction of clinical trials and the latest developments.

#3 - The FDA Speaks Up For Quality Management: Must They Beg?

The FDA's quality by design and risk-based monitoring messaging began more than 10 years ago with their guidance on RBM. 11 years, 5 total related key guidance documents, and 1 global pandemic later, why aren’t we moving forward at more than a snail’s pace?

#4 - The Importance Of Diversity In Clinical Trials: A Comprehensive Analysis

Diversity in clinical trials is vital for advancing research and ensuring equitable care. Explore the significance of diversity, the DEPICT Act's role, and collaborative efforts to foster inclusivity.

#5 - FDA Guidance On Standardizing Diversity And Inclusion Terminology And Collection

The FDA recently issued a new draft guidance titled Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products. It represents a step forward in the journey toward increasing diversity in clinical trials and representation of the real-world populations who will use the products in studies.